D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...

4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...

Age-related macular degeneration (AMD) is a common eye condition in older adults that can affect central vision. Geographic atrophy is an advanced form of AMD that causes permanent vision changes.

An announcement from 4D Molecular Therapeutics ( ($FDMT) ) is now available. On November 6, 2025, 4D Molecular Therapeutics announced positive ...

A new technology may allow patients to recover vision for conditions that were previously thought irreversible ...

D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable ...

Kodiak Sciences Inc. announced at the recent American Academy of Ophthalmology meetings that intraocular interleukin-6 inhibition in Phase 3 clinical trials delivered meaningful improvement in vision ...

Kodiak Sciences Inc. , today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third ...

Driven by purpose and innovation, GE HealthCare’s Patient Care Solutions team is transforming how the world experiences health care.